{"componentChunkName":"component---src-templates-chapter-level-2-chapter-level-2-tsx","path":"/topics/contraception-emergency/how-up-to-date-is-this-topic/changes/","result":{"pageContext":{"chapter":{"id":"30374e39-19e0-54bd-bc62-8fda710d4001","slug":"changes","fullItemName":"Changes","depth":2,"htmlHeader":"<!-- begin field 9bda710b-ecc7-4c4e-b6fe-f921e3db19ec --><h2>Changes</h2><!-- end field 9bda710b-ecc7-4c4e-b6fe-f921e3db19ec -->","summary":null,"htmlStringContent":"<!-- begin item 08889d22-42bc-48cb-a5cd-2421002f8d7c --><!-- begin field e0863f95-cbf3-4088-992b-36074083efb3 --><p><strong>February 2021 </strong>— reviewed. A literature search was conducted in January 2021 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials published since the last revision of the topic. </p><ul><li>The topic structure has been changed.</li><li>Recommendations have been clarified in line with the updated Faculty of Sexual and Reproductive Healthcare (FSRH) guideline <em>Emergency contraception (March 2017, amended December 2020) </em>[FSRH, 2020].</li><li>The Quality and Outcomes Framework (QOF) indicators listed below have been removed as they were retired in April 2019 [BMA and NHS England, 2019/20].<ul><li>CON001: The contractor establishes and maintains a register of women aged 54 or under who have been prescribed any method of contraception at least once in the last year, or other clinically appropriate interval e.g. last 5 years for an IUS.</li><li>CON003: The percentage of women, on the register, prescribed emergency hormonal contraception one or more times in the preceding 12 months by the contractor who have received information from the contractor about long-acting reversible contraception at the time or within one month of the prescription.</li></ul></li></ul><!-- end field e0863f95-cbf3-4088-992b-36074083efb3 --><!-- end item 08889d22-42bc-48cb-a5cd-2421002f8d7c -->","topic":{"id":"34b55d4c-9cac-525d-86dc-99cef03c6806","topicId":"9cd56dfa-04c2-427b-b19d-f31d21101fcf","topicName":"Contraception - emergency","slug":"contraception-emergency","lastRevised":"February 2021","chapters":[{"id":"1b6cbbf8-da0c-5fb6-b093-e2d3c5572c11","fullItemName":"Summary","slug":"summary","subChapters":[]},{"id":"2989e386-a7c8-5dfe-be90-e6943a9877ef","fullItemName":"Have I got the right topic?","slug":"have-i-got-the-right-topic","subChapters":[]},{"id":"74dc3e64-bbad-528b-906a-a8601cc2ba5d","fullItemName":"How up-to-date is this topic?","slug":"how-up-to-date-is-this-topic","subChapters":[{"id":"30374e39-19e0-54bd-bc62-8fda710d4001","slug":"changes","fullItemName":"Changes"},{"id":"9ff3bda9-0586-5b0e-b7ee-71fca4a46217","slug":"update","fullItemName":"Update"}]},{"id":"70ba6931-c855-5dfc-9648-c4e96af62c28","fullItemName":"Goals and outcome measures","slug":"goals-outcome-measures","subChapters":[{"id":"d140f826-870b-5b1d-930f-fae9d8becf7d","slug":"goals","fullItemName":"Goals"},{"id":"43508403-5950-574a-a205-d99d46e212d3","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"a459bdcb-4c8b-5ec7-a58a-b1388d668be2","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"954d04db-f8fb-5cf7-b20d-fabe1ea4d9a5","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"c8b415dd-c103-5034-8775-8da2e419a7d9","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - options for local implementation"},{"id":"70825b99-5fd2-536c-8f45-3be301c38418","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"55f26b80-2a05-5f41-9391-83a93ef8e35f","fullItemName":"Background information","slug":"background-information","subChapters":[{"id":"44b97a41-f563-505c-bf6b-3a68428f5de6","slug":"definition","fullItemName":"Definition"},{"id":"66b12635-36ac-5e3e-8b27-96c86116aaf5","slug":"available-methods","fullItemName":"Available methods"},{"id":"d5554b35-952b-5ff7-9775-99ae976c98ea","slug":"mode-of-action","fullItemName":"Mode of action"},{"id":"0f4766cd-a6cc-5421-9dae-55e1e6f95474","slug":"efficacy","fullItemName":"Efficacy"},{"id":"8becba3f-f7c7-595c-bf5d-c478d64406a9","slug":"advantages-disadvantages","fullItemName":"Advantages and disadvantages"},{"id":"95c6136e-5abb-59f4-9e69-a300ffa8ae5b","slug":"where-to-obtain-emergency-contraception","fullItemName":"Where to obtain emergency contraception"}]},{"id":"ad8d32de-a804-5db6-a703-31de5d377c53","fullItemName":"Management","slug":"management","subChapters":[{"id":"2725764e-0d81-5172-adbc-548550b28479","slug":"management","fullItemName":"Scenario: Management"}]},{"id":"8474bad2-5937-5c2f-b8d5-e7456df9b422","fullItemName":"Supporting evidence","slug":"supporting-evidence","subChapters":[]},{"id":"ebabd585-93a7-5f5d-ab3b-4cd5bf562f0a","fullItemName":"How this topic was developed","slug":"how-this-topic-was-developed","subChapters":[{"id":"f89aa991-bafc-54c0-bbaa-527b5e4c5be0","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"cc96bca5-24a4-5e19-a298-02b088b18c3a","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"dea5d633-048c-5093-acf5-566601be374b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"dacfc7ec-129c-5684-8b24-1317952f7877","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"51674ea1-fc7f-565b-a479-c23d1e0cefac","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"32694ff7-74d1-5732-bc83-7d191dc81196","fullItemName":"References","slug":"references","subChapters":[]}]},"parentChapter":{"id":"74dc3e64-bbad-528b-906a-a8601cc2ba5d","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?"},"subChapters":[{"id":"81eb6d67-a20f-5678-92c0-3546dbccd9bc","slug":"previous-changes","fullItemName":"Previous changes","depth":3,"htmlHeader":"<!-- begin field d2b9b369-f3b7-44d4-b6f8-929005efbb0a --><h3>Previous changes</h3><!-- end field d2b9b369-f3b7-44d4-b6f8-929005efbb0a -->","summary":null,"htmlStringContent":"<!-- begin item a28157f0-8ac8-42cd-9c6a-bc0a5fc32ad0 --><!-- begin field e02732aa-ed0f-4498-9bdf-ee1ffd1aba03 --><p><strong>November 2020 </strong>— minor update. Recommendations on restarting combined hormonal contraception after taking ulipristal acetate emergency contraception have been updated in line with the Faculty of Sexual and Reproductive Healthcare (FSRH) Clinical Effectiveness Unit statement, <em>Response to Recent Publication Regarding Banh, et al</em>.</p><p><strong>July 2020</strong> — minor update. Information on emergency contraception available for young people has been updated in line with the revised manufacturer's SPC. </p><p><strong>March 2020</strong> – minor update. The indications for emergency contraception have been updated in line with the FSRH clinical guidelines <em>Recommended actions after incorrect use of combined hormonal contraception.</em></p><p><strong>September 2019</strong> — minor update. Information added in line with the FSRH clinical guideline <em>Emergency contraception </em>[<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-emergency/references/\">FSRH, 2017a</a>], which states that women should be advised that the available evidence suggests that oral emergency contraception administered after ovulation is ineffective.</p><p><strong>February 2017</strong> — minor update. Information on drug interactions has been updated in line with the FSRH guideline <em>Drug interactions with hormonal contraception</em> [<a class=\"bibliography-reference internal-reference\" href=\"/topics/contraception-emergency/references/\">FSRH, 2017b</a>].</p><p><strong>October 2016</strong> — minor update. Update to SPC for Levonelle1500 microgram tablet to add avoidance of breastfeeding for a minimum of 8 hours following administration.</p><p><strong>April to June 2016</strong> — reviewed. A literature search was conducted in April 2016 to identify evidence-based guidelines, UK policy, systematic reviews, and key randomized controlled trials (RCTs) published since the last revision of the topic. Minor structural changes have been made.</p><p><strong>February 2015</strong> — minor update. Additional information added regarding the availability of two new levonorgestrel 1.5 mg tablets (Isteranda® and Upostelle®) for use as emergency contraception.</p><p><strong>August 2014</strong> — minor update. The Medicines and Healthcare products Regulatory Agency (MHRA) guidance that emergency contraceptives (levonorgestrel and ulipristal acetate) are suitable for all women regardless of body weight or body mass index has been added [MHRA, 2014].</p><p><strong>June 2013 </strong>— minor update. The 2013 Quality Outcomes Framework (QOF) options for local implementation have been added to this topic.</p><p><strong>April 2013</strong> — minor update. The text has been updated in line with the updated FSRH guidance <em>Use of ulipristal acetate (ellaOne®) in breastfeeding women</em> (2013).</p><p><strong>March 2013</strong> — minor update. The telephone number for NHS Direct has been updated.</p><p><strong>January 2013</strong> — minor update. Removed the black triangle status from ulipristal acetate as it is no longer a black triangle drug.</p><p><strong>June 2012</strong> — minor update. The Follow up and after care node has been updated to include a recommendation based on the QOF indicators (2012). According to the QOF indicators, women should be offered verbal and/or written advice about long-acting reversible contraceptives because they do not depend on the woman remembering to use them, therefore the risk of pregnancy is reduced.</p><p><strong>January 2012</strong> — minor update. Topic updated to include a new recommendation from the FSRH guideline <em>Emergency contraception (2012). </em>The FSRH now recommends that all eligible women presenting between 0 and 120 hours of unprotected sexual intercourse or within 5 days of expected ovulation should be offered a copper intrauterine device because of the low documented failure rate. Issued in February 2012.</p><p><strong>October 2011</strong> — topic revised in line with the updated FSRH guidance <em>Emergency contraception</em> (2011). </p><p><strong>June 2011</strong> — minor update. Minor wording changes in the sections on indications for emergency contraception and initiation/continuing hormonal contraception after levonorgestrel. Issued in June 2011.</p><p><strong>May 2011</strong> — minor update. Recommendations on the indications for emergency contraception amended in response to updated guidance from the FSRH Clinical Effectiveness Unit on missed combined oral contraceptive pills (2011). </p><p><strong>March 2011</strong> — topic revised. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence.</p><p><strong>February 2010</strong> — minor update. A newly published RCT comparing ulipristal acetate with levonorgestrel has been added to the Supporting evidence section. Issued in February 2010.</p><p><strong>November 2009</strong> — updated to include ulipristal acetate (ellaOne®), a selective progesterone receptor modulator licensed for emergency contraception up to 120 hours after unprotected sex or contraceptive failure. Issued in January 2010.</p><p><strong>April 2009</strong> — minor typographical error corrected. Issued in May 2009.</p><p><strong>March 2009</strong> — minor update. The Quality and Outcomes Framework (QOF) indicators for sexual health have been updated. Issued in April 2009.</p><p><strong>December 2006 to March 2007</strong> — converted from CKS guidance to CKS topic structure. The evidence base has been reviewed in detail, and recommendations are more clearly justified and transparently linked to the supporting evidence. There are no major changes to the recommendations.</p><p><strong>October 2005</strong> — updated to include the new recommendations on missed pills from the FSRH Clinical Effectiveness Unit (2005). Also, Levonelle-2® has been discontinued and replaced by Levonelle® 1500 microgram tablet; prescribing information and prescriptions have been updated. Issued in November 2005.</p><p><strong>July 2005</strong> — minor update to include text regarding Levonelle One-Step®, a new levonorgestrel emergency contraception product. Issued in July 2005.</p><p><strong>September 2004</strong> — updated to include the World Health Organization (WHO) Medical Eligibility Criteria relating to contraception (2004).</p><p><strong>August 2003</strong> — reviewed. Validated in December 2003 and issued in February 2004.</p><p><strong>January 2001</strong> — written.</p><!-- end field e02732aa-ed0f-4498-9bdf-ee1ffd1aba03 --><!-- end item a28157f0-8ac8-42cd-9c6a-bc0a5fc32ad0 -->","subChapters":[]}]}}},"staticQueryHashes":["3666801979"]}